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INTRODUCTION
Antibodies are slowly eliminated by the reticuloendothelial system where the resulting effect on toxicity towards healthy tissue
during treatment with preparations containing them arises. Radiolanthanides that dissociate from the conjugate in vivo, can form
colloids in the blood stream, increasing the uptake in the liver, or can accumulate in bones due to high affinity of the metal ions to the
phosphate anion which results in myelotoxicity. Radiolabeled monoclonal antibodies (mAbs) intended for radioimmunotherapy (RIT) of
cancers in humans should first be evaluated by preclinical toxicological studies in animal models. Kinetics, distribution and induced
effects in healthy mice/rats for normal tissue toxicity and in animals with implanted tumor are followed. Generalized and
gastrointestinal toxicity, liver toxicity and haemopoietic toxicity are followed. Haemopoietic toxicity, if present, is usually seen within 2-3
weeks after injection of the radiopharmaceutical and resolves within 6-8 weeks, while liver and renal toxicity may require a longer
period of observation (4 - 8 weeks). Ideal radiotherapeutic agent would demonstrate specific anti-tumor effects with minimal to
moderate toxicity to normal tissues. Concerning these facts, in vivo examination of the behavior of Lu- and Y-rituximab-conjugates in
healthy animal models (rats) with particular reference to haematotoxicity was performed.
METHODS
RESULTS
The results from blood analysis showed decrease in value ​​for
RBC in all samples from all groups (without exception) where the
lowest value detected was RBC value determined in the group
treated with Y-p-SCN-Bn-DOTA-rituximab.
This result is in consistence with the confirmed
myelosuppressive activity of rituximab itself and the affinity of the
yttrium to the bone marrow.
On average, in half of the tested samples thrombocythemia
(thrombocytosis) was also observed. It is important to note that
after the completion of treatment (4 weeks after administration of
the last dose) results showed normalization of blood parameters,
i.e. RBC values approaching almost normal values.
Additional in vivo tests for evaluation of rituximab-conjugates in
tumor-bearing animal model are required in order to make a final
characterization for qualification of this formulation for possible
use in RIT for Non-Hodgkin’s lymphoma.
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Schematic process of conjugation and labeling of rituximab-conjugates with different bifunctional chelating agents. 
*This work was supported by IAEA’s Coordinated Research Project (CRP):
Therapeutic radiopharmaceuticals based on 177Lu and 90Y labeled monoclonal
antibodies and peptides: Development and preclinical evaluations.
Application protocol:
In the experimental study six groups (I-VI) of normal rats with 5 animals in each group were used . Each group receives different 
formulation: 
I. Lu- p-SCN-Bn-DOTA-rituximab
II. Lu- p-SCN-Bn-DTPA-rituximab
III. Lu-1B4M-DTPA-rituximab
IV. Y- p-SCN-Bn-DOTA-rituximab
V. Y- p-SCN-Bn-DTPA-rituximab
VI. Y-1B4M-DTPA-rituximab 
Table 1. Results from the blood analysis of animals treated with non-radioactive Lu/Y-
labeled immunoconjugates of rituximab.
Sample
RBC WBC PLT
Referent values
7.21 – 8.45х1012/L 7.2 – 12.6x109/L 250 – 1200x109/L
Mean value for 
Group I
3.40 7.8 1496.5
Mean value for 
Group II
3.05 8.06 558
Mean value for 
Group III
3.69 9.375 984
Mean value for 
Group IV
2.83 10.74 770.66
Mean value for 
Group V
3.288 9.66 1802
Mean value for 
Group VI
3.575 9.10 1332.5
Table 2. Results from the blood analysis of animals treated with non-radioactive Lu/Y-
labeled immunoconjugates of rituximab after 4 weeks from the last dose.
Sample
RBC WBC PLT
Referent values
7.21 – 8.45х1012/L 7.2 – 12.6x109/L 250 – 1200x109/L
Mean value for 
Group I
6.90 6.50 652
Mean value for 
Group II
5.39 1.80 71
Mean value for 
Group III
7.05 3.80 963
Mean value for 
Group IV
4.21 0.70 30
Mean value for 
Group V
6.80 7.10 824
Mean value for 
Group VI
6.98 3.30 1075
